REG - Scancell Hlds - Notice of AGM <Origin Href="QuoteRef">SCLP.L</Origin>

Scancell HoldingsAnnouncement

14/09/2017 07:31

RNS Number : 6869Q
Scancell Holdings Plc
14 September 2017
14 September 2017
Scancell Holdings Plc
("Scancell" or the "Company")
Notice of AGM
Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, will host its Annual General Meeting on Tuesday 10 October 2017.
The AGM details are as follows:
Date:
Tuesday 10 October 2017
Time:
2.00pm
Venue:
The Kassam Stadium
Grenoble Road
Oxford
OX4 4XP
For Further Information: 
Dr John Chiplin, Executive Chairman
Dr Richard Goodfellow, CEO
Scancell Holdings Plc
+1 858 900 2646
+44 (0) 20 3727 1000



Freddy Crossley (Corporate Finance)
Tom Salvesen (Corporate Broking)
Panmure Gordon & Co
+44 (0) 20 7886 2500



Mo Noonan/Simon Conway
FTI Consulting
+44 (0) 20 3727 1000
About Scancell 
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms. 
Scancell's first ImmunoBody, SCIB1 is being developed for the treatment of melanoma.Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence. 
Scancell's ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells. 
Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.Experimental data suggests that the high avidity T cells induced by ImmunoBody vaccines increase expression of PDL-1 on the tumour cell surface, thereby making the tumours more sensitive to checkpoint inhibitor drugs.Re-challenging animals with tumour cells after SCIB1 treatment resulted in 100% survival suggesting that ImmunoBody induces a powerful memory response.Such an effect has not been observed with checkpoint inhibitors. 
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity.The Directors believe that the Moditope platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NOABLGDCXDBBGRX